General Overview of Organic Cation Transporters in Brain.
Antidepressants
Monoamine neurotransmitters
Neurotransmitter reuptake inhibitors
OCT1
OCT2
OCT3
Organic cation transporters
PMAT
Psychotropic drugs
Journal
Handbook of experimental pharmacology
ISSN: 0171-2004
Titre abrégé: Handb Exp Pharmacol
Pays: Germany
ID NLM: 7902231
Informations de publication
Date de publication:
2021
2021
Historique:
pubmed:
31
3
2021
medline:
29
10
2021
entrez:
30
3
2021
Statut:
ppublish
Résumé
Inhibitors of Na
Identifiants
pubmed: 33782773
doi: 10.1007/164_2021_449
doi:
Substances chimiques
Cations
0
Organic Cation Transport Proteins
0
Norepinephrine
X4W3ENH1CV
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-39Informations de copyright
© 2021. The Author(s).
Références
Adamsen D, Ramaekers V, Ho HT, Britschgi C, Rufenacht V, Meili D, Bobrowski E, Philippe P, Nava C, Van Maldergem L, Bruggmann R, Walitza S, Wang J, Grunblatt E, Thony B (2014) Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene. Mol Autism 5:43. https://doi.org/10.1186/2040-2392-5-43
doi: 10.1186/2040-2392-5-43
pubmed: 25802735
pmcid: 4370364
Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, Norinder U, Bergström CAS, Artursson P (2008) Structural requirements for drug inhibition of the liver specific human organic cation transport protein. J Med Chem 51:5932–5942
pubmed: 18788725
doi: 10.1021/jm8003152
Ahlin G, Chen L, Lazorova L, Chen Y, Ianculescu AG, Davis RL, Giacomini KM, Artursson P (2011) Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. Pharmacogenomics J 11:400–411
pubmed: 20567254
doi: 10.1038/tpj.2010.54
Amphoux A, Vialou V, Drescher E, Brüss M, La Cour CM, Rochat C, Millan MJ, Giros B, Bönisch H, Gautron S (2006) Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 8:941–952
doi: 10.1016/j.neuropharm.2006.01.005
Apparsundaram S, Stockdale DJ, Henningsen RA, Milla ME, Martin RS (2008) Antidepressants targeting the serotonin reuptake transporter act via a competitive mechanism. J Pharmacol Exp Ther 327:982–990. https://doi.org/10.1124/jpet.108.142315
doi: 10.1124/jpet.108.142315
pubmed: 18801947
Arndt P, Volk C, Gorboulev V, Budiman T, Popp C, Ulzheimer-Teuber I, Akhoundova A, Koppatz S, Bamberg E, Nagel G, Koepsell H (2001) Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol 281:F454–F468. https://doi.org/10.1152/ajprenal.2001.281.3.F454
doi: 10.1152/ajprenal.2001.281.3.F454
pubmed: 11502595
Bachtell RK, Whisler K, Karanian D, Self DW (2005) Effects of intra-nucleus accumbens shell administration of dopamine agonists and antagonists on cocaine-taking and cocaine-seeking behaviors in the rat. Psychopharmacology (Berl) 183:41–53. https://doi.org/10.1007/s00213-005-0133-1
doi: 10.1007/s00213-005-0133-1
Bacq A, Balasse L, Biala G, Guiard B, Gardier AM, Schinkel A, Louis F, Vialou V, Martres MP, Chevarin C, Hamon M, Giros B, Gautron S (2012) Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response. Mol Psychiatry 17:926–939. mp201187 [pii]. https://doi.org/10.1038/mp.2011.87
Baganz NL, Horton RE, Calderon AS, Owens WA, Munn JL, Watts LT, Koldzic-Zivanovic C, Jeske NA, Koek W, Toney GM, Daws LC (2008) Organic cation transporter 3: keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice. Proc Natl Acad Sci U S A 105:18976–18981. https://doi.org/10.1073/pnas.0800466105
doi: 10.1073/pnas.0800466105
pubmed: 19033200
pmcid: 2596260
Bai M, Ma Z, Sun D, Zheng C, Weng Y, Yang X, Jiang T, Jiang H (2017) Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol 91:3873–3884. https://doi.org/10.1007/s00204-017-2008-8
doi: 10.1007/s00204-017-2008-8
pubmed: 28597291
Bednarczyk D, Ekins S, Wikel JH, Wright SH (2003) Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol 63:489–498
pubmed: 12606755
doi: 10.1124/mol.63.3.489
Belzer M, Morales M, Jagadish B, Mash EA, Wright SH (2013) Substrate-dependent ligand inhibition of the human organic cation transporter OCT2. J Pharmacol Exp Ther 346:300–310. https://doi.org/10.1124/jpet.113.203257
doi: 10.1124/jpet.113.203257
pubmed: 23709117
pmcid: 3716314
Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heils A, Mössner R, Westphal H, Lesch KP (1998) Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine (“Ecstasy”) in serotonin transporter-deficient mice. Mol Pharmacol 53:649–655. https://doi.org/10.1124/mol.53.4.649
Blakely RD, Berson HE, Fremeau RT Jr, Caron MG, Peek MM, Prince HK, Bradley CC (1991) Cloning and expression of a functional serotonin transporter from rat brain. Nature 354:66–70. https://doi.org/10.1038/354066a0
doi: 10.1038/354066a0
pubmed: 1944572
Bowton E, Saunders C, Reddy IA, Campbell NG, Hamilton PJ, Henry LK, Coon H, Sakrikar D, Veenstra-VanderWeele JM, Blakely RD, Sutcliffe J, Matthies HJ, Erreger KGalli A (2014) SLC6A3 coding variant Ala559Val found in two autism probands alters dopamine transporter function and trafficking. Transl Psychiatry 4:e464. https://doi.org/10.1038/tp.2014.90
doi: 10.1038/tp.2014.90
pubmed: 25313507
pmcid: 4350523
Boxberger KH, Hagenbuch B, Lampe JN (2014) Common drugs inhibit human organic cation transporter 1 (OCT1)-mediated neurotransmitter uptake. Drug Metab Dispos 42:990–995. https://doi.org/10.1124/dmd.113.055095
doi: 10.1124/dmd.113.055095
pubmed: 24688079
pmcid: 4014663
Boxberger KH, Hagenbuch B, Lampe JN (2018) Ligand-dependent modulation of hOCT1 transport reveals discrete ligand binding sites within the substrate translocation channel. Biochem Pharmacol 156:371–384. S0006-2952(18)30354-X [pii]. https://doi.org/10.1016/j.bcp.2018.08.028
Breidert T, Spitzenberger F, Gründemann D, Schömig E (1998) Catecholamine transport by the organic cation transporter type 1 (OCT1). Br J Pharmacol 125:218–224. https://doi.org/10.1038/sj.bjp.0702065
doi: 10.1038/sj.bjp.0702065
pubmed: 9776363
pmcid: 1565608
Brigman JL, Mathur P, Harvey-White J, Izquierdo A, Saksida LM, Bussey TJ, Fox S, Deneris E, Murphy DL, Holmes A (2010) Pharmacological or genetic inactivation of the serotonin transporter improves reversal learning in mice. Cereb Cortex 20:1955–1963. https://doi.org/10.1093/cercor/bhp266
doi: 10.1093/cercor/bhp266
pubmed: 20032063
Brust P, Friedrich A, Krizbai IA, Bergmann R, Roux F, Ganapathy V, Johannsen B (2000) Functional expression of the serotonin transporter in immortalized rat brain microvessel endothelial cells. J Neurochem 74:1241–1248. https://doi.org/10.1046/j.1471-4159.2000.741241.x
doi: 10.1046/j.1471-4159.2000.741241.x
pubmed: 10693957
Bunin MA, Wightman RM (1998) Quantitative evaluation of 5-hydroxytryptamine (serotonin) neuronal release and uptake: an investigation of extrasynaptic transmission. J Neurosci 18:4854–4860
pubmed: 9634551
pmcid: 6792557
doi: 10.1523/JNEUROSCI.18-13-04854.1998
Bunin MA, Wightman RM (1999) Paracrine neurotransmission in the CNS: involvement of 5-HT. Trends Neurosci 22:377–382. https://doi.org/10.1016/s0166-2236(99)01410-1
doi: 10.1016/s0166-2236(99)01410-1
pubmed: 10441294
Busch AE, Quester S, Ulzheimer JC, Gorboulev V, Akhoundova A, Waldegger S, Lang F, Koepsell H (1996) Monoamine neurotransmitter transport mediated by the polyspecific cation transporter rOCT1. FEBS Lett 395:153–156
pubmed: 8898084
doi: 10.1016/0014-5793(96)01030-7
Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, Volk C, Arndt P, Ulzheimer JC, Sonders MS, Baumann C, Waldegger S, Lang F, Koepsell H (1998) Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 54:342–352
pubmed: 9687576
doi: 10.1124/mol.54.2.342
Campbell NG, Shekar A, Aguilar JI, Peng D, Navratna V, Yang D, Morley AN, Duran AM, Galli G, O'Grady B, Ramachandran R, Sutcliffe JS, Sitte HH, Erreger K, Meiler J, Stockner T, Bellan LM, Matthies HJG, Gouaux E, McHaourab HS, Galli A (2019) Structural, functional, and behavioral insights of dopamine dysfunction revealed by a deletion in SLC6A3. Proc Natl Acad Sci U S A 116:3853–3862. https://doi.org/10.1073/pnas.1816247116
doi: 10.1073/pnas.1816247116
pubmed: 30755521
pmcid: 6397532
Carboni E, Tanda GL, Frau R, Di Chiara G (1990) Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55:1067–1070. https://doi.org/10.1111/j.1471-4159.1990.tb04599.x
doi: 10.1111/j.1471-4159.1990.tb04599.x
pubmed: 2117046
Cerruti C, Walther DM, Kuhar MJ, Uhl GR (1993) Dopamine transporter mRNA expression is intense in rat midbrain neurons and modest outside midbrain. Brain Res Mol Brain Res 18:181–186. https://doi.org/10.1016/0169-328x(93)90187-t
doi: 10.1016/0169-328x(93)90187-t
pubmed: 8479287
Chang AS, Chang SM, Starnes DM, Schroeter S, Bauman AL, Blakely RD (1996) Cloning and expression of the mouse serotonin transporter. Brain Res Mol Brain Res 43:185–192. https://doi.org/10.1016/s0169-328x(96)00172-6
doi: 10.1016/s0169-328x(96)00172-6
pubmed: 9037532
Chaves C, Campanelli F, Chapy H, Gomez-Zepeda D, Glacial F, Smirnova M, Taghi M, Pallud J, Perriere N, Decleves X, Menet MC, Cisternino S (2020) An interspecies molecular and functional study of organic cation transporters at the blood-brain barrier: from rodents to humans. Pharmaceutics 12. https://doi.org/10.3390/pharmaceutics12040308
Chen L, Shu Y, Liang X, Chen EC, Yee SW, Zur AA, Li S, Xu L, Keshari KR, Lin MJ, Chien HC, Zhang Y, Morrissey KM, Liu J, Ostrem J, Younger NS, Kurhanewicz J, Shokat KM, Ashrafi K, Giacomini KM (2014) OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A 111:9983–9988. 1314939111 [pii]. https://doi.org/10.1073/pnas.1314939111
Chen EC, Khuri N, Liang X, Stecula A, Chien HC, Yee SW, Huang Y, Sali A, Giacomini KM (2017a) Discovery of competitive and noncompetitive ligands of the organic cation transporter 1 (OCT1; SLC22A1). J Med Chem 60:2685–2696. https://doi.org/10.1021/acs.jmedchem.6b01317
doi: 10.1021/acs.jmedchem.6b01317
pubmed: 28230985
Chen J, Brockmöller J, Seitz T, König J, Chen X, Tzvetkov MV (2017b) Tropane alkaloids as substrates and inhibitors of human organic cation transporters of the SLC22 (OCT) and the SLC47 (MATE) families. Biol Chem 398:237–249. https://doi.org/10.1515/hsz-2016-0236 . j/bchm.just-accepted/hsz-2016-0236/hsz-2016-0236.xml [pii]
Choudhuri S, Cherrington NJ, Li N, Klaassen CD (2003) Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. Drug Metab Dispos 31:1337–1345
pubmed: 14570765
doi: 10.1124/dmd.31.11.1337
Ciliax BJ, Heilman C, Demchyshyn LL, Pristupa ZB, Ince E, Hersch SM, Niznik HB, Levey AI (1995) The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 15:1714–1723
pubmed: 7534339
pmcid: 6578165
doi: 10.1523/JNEUROSCI.15-03-01714.1995
Clarke DE, Jones CJ, Linley PA (1969) Histochemical fluorescence studies on noradrenaline accumulation by Uptake 2 in the isolated rat heart. Br J Pharmacol 37:1–9. https://doi.org/10.1111/j.1476-5381.1969.tb09515.x
doi: 10.1111/j.1476-5381.1969.tb09515.x
pubmed: 5824932
pmcid: 1703764
Clements JD (1996) Transmitter timecourse in the synaptic cleft: its role in central synaptic function. Trends Neurosci 19:163–171. https://doi.org/10.1016/s0166-2236(96)10024-2
doi: 10.1016/s0166-2236(96)10024-2
pubmed: 8723198
Cohen Z, Bonvento G, Lacombe P, Hamel E (1996) Serotonin in the regulation of brain microcirculation. Prog Neurobiol 50:335–362. https://doi.org/10.1016/s0301-0082(96)00033-0
doi: 10.1016/s0301-0082(96)00033-0
pubmed: 9004349
Courousse T, Gautron S (2015) Role of organic cation transporters (OCTs) in the brain. Pharmacol Ther 146:94–103. S0163-7258(14)00170-3 [pii]. https://doi.org/10.1016/j.pharmthera.2014.09.008
Courousse T, Bacq A, Belzung C, Guiard B, Balasse L, Louis F, Le Guisquet AM, Gardier AM, Schinkel AH, Giros B, Gautron S (2014) Brain organic cation transporter 2 controls response and vulnerability to stress and GSK3beta signaling. Mol Psychiatry 7:889–900. mp201486 [pii]. https://doi.org/10.1038/mp.2014.86
doi: 10.1038/mp.2014.86
Cui M, Aras R, Christian WV, Rappold PM, Hatwar M, Panza J, Jackson-Lewis V, Javitch JA, Ballatori N, Przedborski S, Tieu K (2009) The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A 106:8043–8048. 0900358106 [pii]. https://doi.org/10.1073/pnas.0900358106
Dahlin A, Xia L, Kong W, Hevner R, Wang J (2007) Expression and immunolocalization of the plasma membrane monoamine transporter in the brain. Neuroscience 146:1193–1211. https://doi.org/10.1016/j.neuroscience.2007.01.072
doi: 10.1016/j.neuroscience.2007.01.072
pubmed: 17408864
Dahlin A, Royall J, Hohmann JG, Wang J (2009) Expression profiling of the solute carrier gene family in the mouse brain. J Pharmacol Exp Ther 329:558–570. jpet.108.149831 [pii]. https://doi.org/10.1124/jpet.108.149831
Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909. https://doi.org/10.1016/s0896-6273(03)00568-3
doi: 10.1016/s0896-6273(03)00568-3
pubmed: 12971891
David DJ, Bourin M, Jego G, Przybylski C, Jolliet P, Gardier AM (2003) Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. Br J Pharmacol 140:1128–1136. https://doi.org/10.1038/sj.bjp.0705538 . sj.bjp.0705538 [pii]
doi: 10.1038/sj.bjp.0705538
pubmed: 14530210
pmcid: 1574124
Daws LC (2009) Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. Pharmacol Ther 121:89–99. https://doi.org/10.1016/j.pharmathera.2008.10.004
Daws LC, Gould GG (2011) Ontogeny and regulation of the serotonin transporter: providing insights into human disorders. Pharmacol Ther 131:61–79. https://doi.org/10.1016/j.pharmthera.2011.03.013
doi: 10.1016/j.pharmthera.2011.03.013
pubmed: 21447358
pmcid: 3131109
Deneris ES, Wyler SC (2012) Serotonergic transcriptional networks and potential importance to mental health. Nat Neurosci 15:519–527. https://doi.org/10.1038/nn.3039
doi: 10.1038/nn.3039
pubmed: 22366757
pmcid: 3594782
dos Santos Pereira JN, Tadjerpisheh S, Abu AM, Saadatmand AR, Weksler B, Romero IA, Couraud PO, Brockmöller J, Tzvetkov MV (2014) The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family. AAPS J 16:1247–1258. https://doi.org/10.1208/s12248-014-9649-9
Dreher JC, Kohn P, Kolachana B, Weinberger DR, Berman KF (2009) Variation in dopamine genes influences responsivity of the human reward system. Proc Natl Acad Sci U S A 106:617–622. https://doi.org/10.1073/pnas.0805517106
doi: 10.1073/pnas.0805517106
pubmed: 19104049
Duan H, Wang J (2010) Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther 335:743–753. https://doi.org/10.1124/jpet.110.170142
doi: 10.1124/jpet.110.170142
pubmed: 20858707
pmcid: 2993547
Duan H, Wang J (2013) Impaired monoamine and organic cation uptake in choroid plexus in mice with targeted disruption of the plasma membrane monoamine transporter (Slc29a4) gene. J Biol Chem 288:3535–3544. https://doi.org/10.1074/jbc.M112.436972
doi: 10.1074/jbc.M112.436972
pubmed: 23255610
Duan H, Hu T, Foti RS, Pan Y, Swaan PW, Wang J (2015) Potent and selective inhibition of plasma membrane monoamine transporter by HIV protease inhibitors. Drug Metab Dispos 43:1773–1780. https://doi.org/10.1124/dmd.115.064824
doi: 10.1124/dmd.115.064824
pubmed: 26285765
pmcid: 4613949
Engel K, Wang J (2005) Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol Pharmacol 68:1397–1407. mol.105.016832 [pii]. https://doi.org/10.1124/mol.105.016832
Engel K, Zhou M, Wang J (2004) Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem 279:50042–50049. https://doi.org/10.1074/jbc.M407913200
doi: 10.1074/jbc.M407913200
pubmed: 15448143
Eshleman AJ, Henningsen RA, Neve KA, Janowsky A (1994) Release of dopamine via the human transporter. Mol Pharmacol 45:312–316
pubmed: 7906856
Floerl S, Kuehne A, Hagos Y (2020) Functional and pharmacological comparison of human, mouse, and rat organic cation transporter 1 toward drug and pesticide interaction. Int J Mol Sci 21. https://doi.org/10.3390/ijms21186871
Fraser-Spears R, Krause-Heuer AM, Basiouny M, Mayer FP, Manishimwe R, Wyatt NA, Dobrowolski JC, Roberts MP, Greguric I, Kumar N, Koek W, Sitte HH, Callaghan PD, Fraser BH, Daws LC (2019) Comparative analysis of novel decynium-22 analogs to inhibit transport by the low-affinity, high-capacity monoamine transporters, organic cation transporters 2 and 3, and plasma membrane monoamine transporter. Eur J Pharmacol 842:351–364. https://doi.org/10.1016/j.ejphar.2018.10.028
doi: 10.1016/j.ejphar.2018.10.028
pubmed: 30473490
Freed C, Revay R, Vaughan RA, Kriek E, Grant S, Uhl GR, Kuhar MJ (1995) Dopamine transporter immunoreactivity in rat brain. J Comp Neurol 359:340–349. https://doi.org/10.1002/cne.903590211
doi: 10.1002/cne.903590211
pubmed: 7499533
Garbarino VR, Gilman TL, Daws LC, Gould GG (2019) Extreme enhancement or depletion of serotonin transporter function and serotonin availability in autism spectrum disorder. Pharmacol Res 140:85–99. https://doi.org/10.1016/j.phrs.2018.07.010
doi: 10.1016/j.phrs.2018.07.010
pubmed: 30009933
Garris PA, Wightman RM (1994) Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. J Neurosci 14:442–450
pubmed: 8283249
pmcid: 6576851
doi: 10.1523/JNEUROSCI.14-01-00442.1994
Garris PA, Ciolkowski EL, Pastore P, Wightman RM (1994) Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J Neurosci 14:6084–6093
pubmed: 7931564
pmcid: 6577011
doi: 10.1523/JNEUROSCI.14-10-06084.1994
Gasser PJ, Lowry CA, Orchinik M (2006) Corticosterone-sensitive monoamine transport in the rat dorsomedial hypothalamus: potential role for organic cation transporter 3 in stress-induced modulation of monoaminergic neurotransmission. J Neurosci 26:8758–8766. https://doi.org/10.1523/JNEUROSCI.0570-06.2006
doi: 10.1523/JNEUROSCI.0570-06.2006
pubmed: 16928864
pmcid: 6674371
Gasser PJ, Orchinik M, Raju I, Lowry CA (2009) Distribution of organic cation transporter 3, a corticosterone-sensitive monoamine transporter, in the rat brain. J Comp Neurol 512:529–555. https://doi.org/10.1002/cne.21921
doi: 10.1002/cne.21921
pubmed: 19025979
Gasser PJ, Hurley MM, Chan J, Pickel VM (2017) Organic cation transporter 3 (OCT3) is localized to intracellular and surface membranes in select glial and neuronal cells within the basolateral amygdaloid complex of both rats and mice. Brain Struct Funct 222:1913–1928. https://doi.org/10.1007/s00429-016-1315-9
doi: 10.1007/s00429-016-1315-9
pubmed: 27659446
Geier EG, Chen EC, Webb A, Papp AC, Yee SW, Sadee W, Giacomini KM (2013) Profiling solute carrier transporters in the human blood-brain barrier. Clin Pharmacol Ther 94:636–639. clpt2013175 [pii]. https://doi.org/10.1038/clpt.2013.175
Gilman TL, George CM, Vitela M, Herrera-Rosales M, Basiouny MS, Koek W, Daws LC (2018) Constitutive plasma membrane monoamine transporter (PMAT, Slc29a4) deficiency subtly affects anxiety-like and coping behaviours. Eur J Neurosci. https://doi.org/10.1111/ejn.13968
Giros B, el Mestikawy S, Bertrand L, Caron MG (1991) Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett 295:149–154. https://doi.org/10.1016/0014-5793(91)81406-x
doi: 10.1016/0014-5793(91)81406-x
pubmed: 1765147
Giros B, el Mestikawy S, Godinot N, Zheng K, Han H, Yang-Feng T, Caron MG (1992) Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 42:383–390
Giros B, Wang YM, Suter S, McLeskey SB, Pifl C, Caron MG (1994) Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using chimeric dopamine-norepinephrine transporters. J Biol Chem 269:15985–15988
pubmed: 8206893
doi: 10.1016/S0021-9258(17)33961-3
Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606–612. https://doi.org/10.1038/379606a0
doi: 10.1038/379606a0
pubmed: 8628395
Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, Koepsell H (1997) Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16:871–881. https://doi.org/10.1089/dna.1997.16.871
doi: 10.1089/dna.1997.16.871
pubmed: 9260930
Graf EN, Wheeler RA, Baker DA, Ebben AL, Hill JE, McReynolds JR, Robble MA, Vranjkovic O, Wheeler DS, Mantsch JR, Gasser PJ (2013) Corticosterone acts in the nucleus accumbens to enhance dopamine signaling and potentiate reinstatement of cocaine seeking. J Neurosci 33:11800–11810. https://doi.org/10.1523/JNEUROSCI.1969-13.2013
doi: 10.1523/JNEUROSCI.1969-13.2013
pubmed: 23864669
pmcid: 3713722
Gründemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H (1994) Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372:549–552. https://doi.org/10.1038/372549a0
doi: 10.1038/372549a0
pubmed: 7990927
Gründemann D, Babin-Ebell J, Martel F, Ording N, Schmidt A, Schömig E (1997) Primary structure and functional expression of the apical organic cation transporter from kidney epithelial LLC-PK1 cells. J Biol Chem 272:10408–10413. https://doi.org/10.1074/jbc.272.16.10408
doi: 10.1074/jbc.272.16.10408
pubmed: 9099681
Gründemann D, Koster S, Kiefer N, Breidert T, Engelhardt M, Spitzenberger F, Obermüller N, Schömig E (1998a) Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem 273:30915–30920. https://doi.org/10.1074/jbc.273.47.30915
doi: 10.1074/jbc.273.47.30915
pubmed: 9812985
Gründemann D, Schechinger B, Rappold GA, Schömig E (1998b) Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci 1:349–351. https://doi.org/10.1038/1557
doi: 10.1038/1557
pubmed: 10196521
Gründemann D, Koschker AC, Haag C, Honold C, Zimmermann T, Schömig E (2002) Activation of the extraneuronal monoamine transporter (EMT) from rat expressed in 293 cells. Br J Pharmacol 137:910–918. https://doi.org/10.1038/sj.bjp.0704926
doi: 10.1038/sj.bjp.0704926
pubmed: 12411423
pmcid: 1573551
Haag C, Berkels R, Gründemann D, Lazar A, Taubert D, Schömig E (2004) The localisation of the extraneuronal monoamine transporter (EMT) in rat brain. J Neurochem 88:291–297
doi: 10.1111/j.1471-4159.2004.02180.x
Hacker K, Maas R, Kornhuber J, Fromm MF, Zolk O (2015) Substrate-dependent inhibition of the human organic cation transporter OCT2: a comparison of metformin with experimental substrates. PLoS One 10:e0136451. https://doi.org/10.1371/journal.pone.0136451 . PONE-D-15-16754 [pii]
doi: 10.1371/journal.pone.0136451
pubmed: 26327616
pmcid: 4556614
Haenisch B, Bönisch H (2010) Interaction of the human plasma membrane monoamine transporter (hPMAT) with antidepressants and antipsychotics. Naunyn Schmiedebergs Arch Pharmacol 381:33–39. https://doi.org/10.1007/s00210-009-0479-8
doi: 10.1007/s00210-009-0479-8
pubmed: 20012264
Hamilton PJ, Campbell NG, Sharma S, Erreger K, Herborg Hansen F, Saunders C, Belovich AN, Consortium NAAS, Sahai MA, Cook EH, Gether U, McHaourab HS, Matthies HJ, Sutcliffe JS, Galli A (2013) De novo mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder. Mol Psychiatry 18:1315–1323. https://doi.org/10.1038/mp.2013.102
doi: 10.1038/mp.2013.102
pubmed: 23979605
pmcid: 4046646
Hasannejad H, Takeda M, Narikawa S, Huang X-L, Enomoto A, Taki K, Niwa T, Jung SH, Onozato ML, Tojo A, Endou H (2004) Human organic cation transporter 3 mediates the transport of antiarrhythmic drugs. Eur J Pharmacol 499:45–51
pubmed: 15363950
doi: 10.1016/j.ejphar.2004.07.098
Hayer-Zillgen M, Brüss M, Bönisch H (2002) Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol 136:829–836
pubmed: 12110607
pmcid: 1573414
doi: 10.1038/sj.bjp.0704785
Hendrickx R, Johansson JG, Lohmann C, Jenvert RM, Blomgren A, Borjesson L, Gustavsson L (2013) Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem 56:7232–7242. https://doi.org/10.1021/jm400966v
doi: 10.1021/jm400966v
pubmed: 23984907
Hersch SM, Yi H, Heilman CJ, Edwards RH, Levey AI (1997) Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J Comp Neurol 388:211–227
pubmed: 9368838
doi: 10.1002/(SICI)1096-9861(19971117)388:2<211::AID-CNE3>3.0.CO;2-4
Hill JE, Gasser PJ (2013) Organic cation transporter 3 is densely expressed in the intercalated cell groups of the amygdala: anatomical evidence for a stress hormone-sensitive dopamine clearance system. J Chem Neuroanat 52:36–43. https://doi.org/10.1016/j.jchemneu.2013.04.007
doi: 10.1016/j.jchemneu.2013.04.007
pubmed: 23694905
Hoffman BJ, Hansson SR, Mezey E, Palkovits M (1998) Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front Neuroendocrinol 19:187–231. https://doi.org/10.1006/frne.1998.0168
doi: 10.1006/frne.1998.0168
pubmed: 9665836
Holleran KM, Rose JH, Fordahl SC, Benton KC, Rohr KE, Gasser PJ, Jones SR (2020) Organic cation transporter 3 and the dopamine transporter differentially regulate catecholamine uptake in the basolateral amygdala and nucleus accumbens. Eur J Neurosci. https://doi.org/10.1111/ejn.14927
Hosford PS, Millar J, Ramage AG (2015) Cardiovascular afferents cause the release of 5-HT in the nucleus tractus solitarii; this release is regulated by the low- (PMAT) not the high-affinity transporter (SERT). J Physiol 593:1715–1729. https://doi.org/10.1113/jphysiol.2014.285312
doi: 10.1113/jphysiol.2014.285312
pubmed: 25694117
pmcid: 4386968
Itagaki S, Ganapathy V, Ho HT, Zhou M, Babu E, Wang J (2012) Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter. Drug Metab Dispos 40:1138–1143. https://doi.org/10.1124/dmd.111.042432
doi: 10.1124/dmd.111.042432
pubmed: 22396231
pmcid: 3362792
Iversen LL (1965) The uptake of catechol amines at high perfusion concentrations in the rat isolated heart: a novel catechol amine uptake process. Br J Pharmacol Chemother 25:18–33. https://doi.org/10.1111/j.1476-5381.1965.tb01753.x
doi: 10.1111/j.1476-5381.1965.tb01753.x
pubmed: 19108196
pmcid: 1510677
Iversen LL (1971) Role of transmitter uptake mechanisms in synaptic neurotransmission. Br J Pharmacol 41:571–591. https://doi.org/10.1111/j.1476-5381.1971.tb07066.x
doi: 10.1111/j.1476-5381.1971.tb07066.x
pubmed: 4397129
pmcid: 1702772
Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci U S A 82:2173–2177
pubmed: 3872460
pmcid: 397515
doi: 10.1073/pnas.82.7.2173
Jones SR, Gainetdinov RR, Wightman RM, Caron MG (1998) Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 18:1979–1986
pubmed: 9482784
pmcid: 6792915
doi: 10.1523/JNEUROSCI.18-06-01979.1998
Kalaria RN, Harik SI (1987) Blood-brain barrier monoamine oxidase: enzyme characterization in cerebral microvessels and other tissues from six mammalian species, including human. J Neurochem 49:856–864. https://doi.org/10.1111/j.1471-4159.1987.tb00973.x
doi: 10.1111/j.1471-4159.1987.tb00973.x
pubmed: 2886556
Keiser M, Hasan M, Oswald S (2018) Affinity of ketamine to clinically relevant transporters. Mol Pharm 15:326–331. https://doi.org/10.1021/acs.molpharmaceut.7b00627
doi: 10.1021/acs.molpharmaceut.7b00627
pubmed: 29191019
Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, Ganapathy V (1998) Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem 273:15971–15979. https://doi.org/10.1074/jbc.273.26.15971
doi: 10.1074/jbc.273.26.15971
pubmed: 9632645
Kido Y, Matsson P, Giacomini KM (2011) Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem 54:4548–4558
pubmed: 21599003
pmcid: 3257218
doi: 10.1021/jm2001629
Kilty JE, Lorang D, Amara SG (1991) Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 254:578–579. https://doi.org/10.1126/science.1948035
doi: 10.1126/science.1948035
pubmed: 1948035
Kitaichi K, Fukuda M, Nakayama H, Aoyama N, Ito Y, Fujimoto Y, Takagi K, Takagi K, Hasegawa T (2005) Behavioral changes following antisense oligonucleotide-induced reduction of organic cation transporter-3 in mice. Neurosci Lett 382:195–200
pubmed: 15911148
doi: 10.1016/j.neulet.2005.03.014
Koepsell H (2019) Multiple binding sites in organic cation transporters require sophisticated procedures to identify interactions of novel drugs. Biol Chem 400:195–207. https://doi.org/10.1515/hsz-2018-0191
doi: 10.1515/hsz-2018-0191
pubmed: 30138103
Koepsell H (2020) Organic cation transporters in health and disease. Pharmacol Rev 72:253–319. https://doi.org/10.1124/pr.118.015578
doi: 10.1124/pr.118.015578
pubmed: 31852803
Koepsell H, Lips K, Volk C (2007) Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24:1227–1251
pubmed: 17473959
doi: 10.1007/s11095-007-9254-z
Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 455:894–902. https://doi.org/10.1038/nature07455
doi: 10.1038/nature07455
pubmed: 2721780
pmcid: 2721780
Kristensen AS, Andersen J, Jorgensen TN, Sorensen L, Eriksen J, Loland CJ, Stromgaard K, Gether U (2011) SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev 63:585–640. https://doi.org/10.1124/pr.108.000869
doi: 10.1124/pr.108.000869
pubmed: 21752877
Lesch KP, Waider J (2012) Serotonin in the modulation of neural plasticity and networks: implications for neurodevelopmental disorders. Neuron 76:175–191. https://doi.org/10.1016/j.neuron.2012.09.013
doi: 10.1016/j.neuron.2012.09.013
pubmed: 23040814
Lesch KP, Araragi N, Waider J, van den Hove D, Gutknecht L (2012) Targeting brain serotonin synthesis: insights into neurodevelopmental disorders with long-term outcomes related to negative emotionality, aggression and antisocial behaviour. Philos Trans R Soc Lond B Biol Sci 367:2426–2443. https://doi.org/10.1098/rstb.2012.0039
doi: 10.1098/rstb.2012.0039
pubmed: 22826343
pmcid: 3405678
Leybaert L (2005) Neurobarrier coupling in the brain: a partner of neurovascular and neurometabolic coupling? J Cereb Blood Flow Metab 25:2–16. https://doi.org/10.1038/sj.jcbfm.9600001
doi: 10.1038/sj.jcbfm.9600001
pubmed: 15678108
Li L, Weng Y, Wang W, Bai M, Lei H, Zhou H, Jiang H (2017) Multiple organic cation transporters contribute to the renal transport of sulpiride. Biopharm Drug Dispos 38:526–534. https://doi.org/10.1002/bdd.2104
doi: 10.1002/bdd.2104
pubmed: 28926871
Lin C-J, Tai Y, Huang M-T, Tsai Y-F, Hsu H-J, Tzen K-Y, Liou H-H (2010) Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents. J Neurochem 114:717–727
pubmed: 20477935
doi: 10.1111/j.1471-4159.2010.06801.x
Liprando LA, Miner LH, Blakely RD, Lewis DA, Sesack SR (2004) Ultrastructural interactions between terminals expressing the norepinephrine transporter and dopamine neurons in the rat and monkey ventral tegmental area. Synapse 52:233–244. https://doi.org/10.1002/syn.20023
doi: 10.1002/syn.20023
pubmed: 15103690
Lorang D, Amara SG, Simerly RB (1994) Cell-type-specific expression of catecholamine transporters in the rat brain. J Neurosci 14:4903–4914
pubmed: 8046459
doi: 10.1523/JNEUROSCI.14-08-04903.1994
Madayag A, Kau KS, Lobner D, Mantsch JR, Wisniewski S, Baker DA (2010) Drug-induced plasticity contributing to heightened relapse susceptibility: neurochemical changes and augmented reinstatement in high-intake rats. J Neurosci 30:210–217. https://doi.org/10.1523/JNEUROSCI.1342-09.2010
doi: 10.1523/JNEUROSCI.1342-09.2010
pubmed: 20053903
pmcid: 2823262
Maruki C, Spatz M, Ueki Y, Nagatsu I, Bembry J (1984) Cerebrovascular endothelial cell culture: metabolism and synthesis of 5-hydroxytryptamine. J Neurochem 43:316–319. https://doi.org/10.1111/j.1471-4159.1984.tb00902.x
doi: 10.1111/j.1471-4159.1984.tb00902.x
pubmed: 6204010
Mathews TA, Fedele DE, Coppelli FM, Avila AM, Murphy DL, Andrews AM (2004) Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J Neurosci Methods 140:169–181. https://doi.org/10.1016/j.jneumeth.2004.05.017
doi: 10.1016/j.jneumeth.2004.05.017
pubmed: 15589347
Matthaei J, Kuron D, Faltraco F, Knoch T, dos Santos Pereira JN, Abu AM, Prukop T, Brockmöller J, Tzvetkov MV (2016) OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther 99:633–641. https://doi.org/10.1002/cpt.317
doi: 10.1002/cpt.317
pubmed: 26659468
Mayer FP, Schmid D, Owens WA, Gould GG, Apuschkin M, Kudlacek O, Salzer I, Boehm S, Chiba P, Williams PH, Wu HH, Gether U, Koek W, Daws LC, Sitte HH (2018) An unsuspected role for organic cation transporter 3 in the actions of amphetamine. Neuropsychopharmacology 43:2408–2417. https://doi.org/10.1038/s41386-018-0053-5
doi: 10.1038/s41386-018-0053-5
pubmed: 29773909
pmcid: 6180071
Mazei-Robinson MS, Blakely RD (2006) ADHD and the dopamine transporter: are there reasons to pay attention? Handb Exp Pharmacol:373–415. https://doi.org/10.1007/3-540-29784-7_17
Mazei-Robison MS, Couch RS, Shelton RC, Stein MA, Blakely RD (2005) Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder. Neuropharmacology 49:724–736. https://doi.org/10.1016/j.neuropharm.2005.08.003
doi: 10.1016/j.neuropharm.2005.08.003
pubmed: 16171832
Mazei-Robison MS, Bowton E, Holy M, Schmudermaier M, Freissmuth M, Sitte HH, Galli A, Blakely RD (2008) Anomalous dopamine release associated with a human dopamine transporter coding variant. J Neurosci 28:7040–7046. https://doi.org/10.1523/JNEUROSCI.0473-08.2008
doi: 10.1523/JNEUROSCI.0473-08.2008
pubmed: 18614672
pmcid: 2573963
Mika J, Zychowska M, Makuch W, Rojewska E, Przewlocka B (2013) Neuronal and immunological basis of action of antidepressants in chronic pain – clinical and experimental studies. Pharmacol Rep 65:1611–1621. https://doi.org/10.1016/s1734-1140(13)71522-6
doi: 10.1016/s1734-1140(13)71522-6
pubmed: 24553009
Millan MJ, Gobert A, Lejeune F, Newman-Tancredi A, Rivet JM, Auclair A, Peglion JL (2001) S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 298:565–580
pubmed: 11454918
Minematsu T, Iwai M, Umehara K-I, Usui T, Kamimura H (2010) Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos 38:1–4
pubmed: 19833842
doi: 10.1124/dmd.109.028142
Miura Y, Yoshikawa T, Naganuma F, Nakamura T, Iida T, Karpati A, Matsuzawa T, Mogi A, Harada R, Yanai K (2017) Characterization of murine polyspecific monoamine transporters. FEBS Open Bio 7:237–248. https://doi.org/10.1002/2211-5463.12183
doi: 10.1002/2211-5463.12183
pubmed: 28174689
pmcid: 5292661
Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 22:389–395
pubmed: 11784783
pmcid: 6758674
doi: 10.1523/JNEUROSCI.22-02-00389.2002
Muck A, Gilsbach R, Lobbe-Werner S, Bruss M, Bönisch H (2007) Molecular cloning and functional expression of the murine noradrenaline transporter. Naunyn Schmiedebergs Arch Pharmacol 376:65–71. https://doi.org/10.1007/s00210-007-0181-7
doi: 10.1007/s00210-007-0181-7
pubmed: 17882401
Müller J, Lips KS, Metzner L, Neubert RHH, Koepsell H, Brandsch M (2005) Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 70:1851–1860
pubmed: 16263091
doi: 10.1016/j.bcp.2005.09.011
Nakayama H, Kitaichi K, Ito Y, Hashimoto K, Takagi K, Yokoi T, Takagi K, Ozaki N, Yamamoto T, Hasegawa T (2007) The role of organic cation transporter-3 in methamphetamine disposition and its behavioral response in rats. Brain Res 1184:260–269
pubmed: 17988657
doi: 10.1016/j.brainres.2007.09.072
Nies AT, Herrmann E, Brom M, Keppler D (2008) Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch Pharmacol 376:449–461
pubmed: 18157518
doi: 10.1007/s00210-007-0219-x
Nies AT, Koepsell H, Damme K, Schwab M (2011) Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol:105–167. https://doi.org/10.1007/978-3-642-14541-4_3
Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM (1996) The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 16:436–447
pubmed: 8551328
pmcid: 6578661
doi: 10.1523/JNEUROSCI.16-02-00436.1996
Nirenberg MJ, Chan J, Pohorille A, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM (1997a) The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens. J Neurosci 17:6899–6907
pubmed: 9278525
pmcid: 6573281
doi: 10.1523/JNEUROSCI.17-18-06899.1997
Nirenberg MJ, Chan J, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM (1997b) Immunogold localization of the dopamine transporter: an ultrastructural study of the rat ventral tegmental area. J Neurosci 17:5255–5262
pubmed: 9204909
pmcid: 6793826
doi: 10.1523/JNEUROSCI.17-14-05255.1997
Okura T, Kato S, Takano Y, Sato T, Yamashita A, Morimoto R, Ohtsuki S, Terasaki T, Deguchi Y (2011) Functional characterization of rat plasma membrane monoamine transporter in the blood-brain and blood-cerebrospinal fluid barriers. J Pharm Sci 100:3924–3938. https://doi.org/10.1002/jps.22594
doi: 10.1002/jps.22594
pubmed: 21538354
Orrico-Sanchez A, Chausset-Boissarie L, Alves de Sousa R, Coutens B, Rezai Amin S, Vialou V, Louis F, Hessani A, Dansette PM, Zornoza T, Gruszczynski C, Giros B, Guiard BP, Acher F, Pietrancosta N, Gautron S (2020) Antidepressant efficacy of a selective organic cation transporter blocker in a mouse model of depression. Mol Psychiatry 25:1245–1259. https://doi.org/10.1038/s41380-019-0548-4
doi: 10.1038/s41380-019-0548-4
pubmed: 31619760
Owens MJ, Morgan WN, Plott SJ, Nemeroff CB (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283:1305–1322
pubmed: 9400006
Pacholczyk T, Blakely RD, Amara SG (1991) Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350:350–354. https://doi.org/10.1038/350350a0
doi: 10.1038/350350a0
pubmed: 2008212
Paczkowski FA, Bryan-Lluka LJ, Porzgen P, Bruss M, Bönisch H (1999) Comparison of the pharmacological properties of cloned rat, human, and bovine norepinephrine transporters. J Pharmacol Exp Ther 290:761–767
pubmed: 10411589
Parsons AA (1991) 5-HT receptors in human and animal cerebrovasculature. Trends Pharmacol Sci 12:310–315. https://doi.org/10.1016/0165-6147(91)90583-e
doi: 10.1016/0165-6147(91)90583-e
pubmed: 1949199
Pickel VM, Chan J (1999) Ultrastructural localization of the serotonin transporter in limbic and motor compartments of the nucleus accumbens. J Neurosci 19:7356–7366
pubmed: 10460242
pmcid: 6782507
doi: 10.1523/JNEUROSCI.19-17-07356.1999
Pittenger C, Bloch MH (2014) Pharmacological treatment of obsessive-compulsive disorder. Psychiatr Clin North Am 37:375–391. https://doi.org/10.1016/j.psc.2014.05.006
doi: 10.1016/j.psc.2014.05.006
pubmed: 25150568
pmcid: 4143776
Qian Y, Melikian HE, Rye DB, Levey AI, Blakely RD (1995) Identification and characterization of antidepressant-sensitive serotonin transporter proteins using site-specific antibodies. J Neurosci 15:1261–1274
pubmed: 7869097
pmcid: 6577805
doi: 10.1523/JNEUROSCI.15-02-01261.1995
Reinhard JF Jr, Liebmann JE, Schlosberg AJ, Moskowitz MA (1979) Serotonin neurons project to small blood vessels in the brain. Science 206:85–87. https://doi.org/10.1126/science.482930
doi: 10.1126/science.482930
pubmed: 482930
Revay R, Vaughan R, Grant S, Kuhar MJ (1996) Dopamine transporter immunohistochemistry in median eminence, amygdala, and other areas of the rat brain. Synapse 22:93–99. https://doi.org/10.1002/(SICI)1098-2396(199602)22:2<93::AID-SYN1>3.0.CO;2-C
doi: 10.1002/(SICI)1098-2396(199602)22:2<93::AID-SYN1>3.0.CO;2-C
pubmed: 8787132
Sandoval PJ, Zorn KM, Clark AM, Ekins S, Wright SH (2018) Assessment of substrate-dependent ligand interactions at the organic cation transporter OCT2 using six model substrates. Mol Pharmacol 94:1057–1068. mol.117.111443 [pii]. https://doi.org/10.1124/mol.117.111443
doi: 10.1124/mol.117.111443
pubmed: 29884691
pmcid: 6070079
Sata R, Ohtani H, Tsujimoto M, Murakami H, Koyabu N, Nakamura T, Uchiumi T, Kuwano M, Nagata H, Tsukimori K, Nakano H, Sawada Y (2005) Functional analysis of organic cation transporter 3 expressed in human placenta. J Pharmacol Exp Ther 315:888–895
pubmed: 16081676
doi: 10.1124/jpet.105.086827
Schmitt A, Mössner R, Gossmann A, Fischer IG, Gorboulev V, Murphy DL, Koepsell H, Lesch KP (2003) Organic cation transporter capable of transporting serotonin is up-regulated in serotonin transporter-deficient mice. J Neurosci Res 71:701–709
pubmed: 12584728
doi: 10.1002/jnr.10521
Schroeter S, Apparsundaram S, Wiley RG, Miner LH, Sesack SR, Blakely RD (2000) Immunolocalization of the cocaine- and antidepressant-sensitive l-norepinephrine transporter. J Comp Neurol 420:211–232
pubmed: 10753308
doi: 10.1002/(SICI)1096-9861(20000501)420:2<211::AID-CNE5>3.0.CO;2-3
Sekhar GN, Fleckney AL, Boyanova ST, Rupawala H, Lo R, Wang H, Farag DB, Rahman KM, Broadstock M, Reeves S, Thomas SA (2019) Region-specific blood-brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer's disease. Fluids Barriers CNS 16:38. https://doi.org/10.1186/s12987-019-0158-1
doi: 10.1186/s12987-019-0158-1
pubmed: 31842924
pmcid: 6915870
Shimada S, Kitayama S, Lin C-L, Patel A, Nanthakumar E, Gregor P, Kuhar M, Uhl G (1991) Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 254:576–578
pubmed: 1948034
doi: 10.1126/science.1948034
Shirasaka Y, Lee N, Duan H, Ho H, Pak J, Wang J (2017) Interspecies comparison of the functional characteristics of plasma membrane monoamine transporter (PMAT) between human, rat and mouse. J Chem Neuroanat 83–84:99–106. https://doi.org/10.1016/j.jchemneu.2016.09.006
doi: 10.1016/j.jchemneu.2016.09.006
pubmed: 27641077
Sinha R, Talih M, Malison R, Cooney N, Anderson GM, Kreek MJ (2003) Hypothalamic-pituitary-adrenal axis and sympatho-adreno-medullary responses during stress-induced and drug cue-induced cocaine craving states. Psychopharmacology (Berl) 170:62–72. https://doi.org/10.1007/s00213-003-1525-8
doi: 10.1007/s00213-003-1525-8
Sitte HH, Freissmuth M (2015) Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci 36:41–50. https://doi.org/10.1016/j.tips.2014.11.006
doi: 10.1016/j.tips.2014.11.006
pubmed: 25542076
Sitte HH, Huck S, Reither H, Boehm S, Singer EA, Pifl C (1998) Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter. J Neurochem 71:1289–1297. https://doi.org/10.1046/j.1471-4159.1998.71031289.x
doi: 10.1046/j.1471-4159.1998.71031289.x
pubmed: 9721755
Smiley JF, Levey AI, Ciliax BJ, Goldman-Rakic PS (1994) D1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: predominant and extrasynaptic localization in dendritic spines. Proc Natl Acad Sci U S A 91:5720–5724. https://doi.org/10.1073/pnas.91.12.5720
doi: 10.1073/pnas.91.12.5720
pubmed: 7911245
pmcid: 44068
Song W, Luo Q, Zhang Y, Zhou L, Liu Y, Ma Z, Guo J, Huang Y, Cheng L, Meng Z, Li Z, Zhang B, Li S, Yee SW, Fan H, Li P, Giacomini KM, Chen L (2019) Organic cation transporter 3 (Oct3) is a distinct catecholamines clearance route in adipocytes mediating the beiging of white adipose tissue. PLoS Biol 17:e2006571. https://doi.org/10.1371/journal.pbio.2006571 . pbio.2006571 [pii]
doi: 10.1371/journal.pbio.2006571
pubmed: 30653498
pmcid: 6336244
Sulzer D, Edwards RH (2005) Antidepressants and the monoamine masquerade. Neuron 46:1–2. https://doi.org/10.1016/j.neuron.2005.03.013
doi: 10.1016/j.neuron.2005.03.013
pubmed: 15820686
Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15:4102–4108
pubmed: 7751968
pmcid: 6578196
doi: 10.1523/JNEUROSCI.15-05-04102.1995
Sun S, Wang K, Lei H, Li L, Tu M, Zeng S, Zhou H, Jiang H (2014) Inhibition of organic cation transporter 2 and 3 may be involved in the mechanism of the antidepressant-like action of berberine. Prog Neuropsychopharmacol Biol Psychiatry 49:1–6. S0278-5846(13)00248-0 [pii]. https://doi.org/10.1016/j.pnpbp.2013.11.005
Sur C, Betz H, Schloss P (1996) Immunocytochemical detection of the serotonin transporter in rat brain. Neuroscience 73:217–231. https://doi.org/10.1016/0306-4522(96)00030-9
doi: 10.1016/0306-4522(96)00030-9
pubmed: 8783244
Sweet DH, Miller DS, Pritchard JB (2001) Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus. J Biol Chem 276:41611–41619. https://doi.org/10.1074/jbc.M108472200
doi: 10.1074/jbc.M108472200
pubmed: 11553644
Takano H, Ito S, Zhang X, Ito H, Zhang MR, Suzuki H, Maeda K, Kusuhara H, Suhara T, Sugiyama Y. (2017) Possible role of organic cation transporters in the distribution of [11C]sulpiride, a dopamine D2 receptor antagonist. J Pharm Sci S0022-3549(17)30359-3 [pii] https://doi.org/10.1016/j.xphs.2017.05.006
Tao-Cheng JH, Zhou FC (1999) Differential polarization of serotonin transporters in axons versus soma-dendrites: an immunogold electron microscopy study. Neuroscience 94:821–830. https://doi.org/10.1016/s0306-4522(99)00373-5
doi: 10.1016/s0306-4522(99)00373-5
pubmed: 10579573
Tatsumi M, Groshan K, Blakely RD, Richelson E (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340:249–258. https://doi.org/10.1016/s0014-2999(97)01393-9
doi: 10.1016/s0014-2999(97)01393-9
pubmed: 9537821
Torres GE, Gainetdinov RR, Caron MG (2003) Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 4:13–25
pubmed: 12511858
doi: 10.1038/nrn1008
Tzvetkov MV, Saadatmand AR, Bokelmann K, Meineke I, Kaiser R, Brockmöller J (2012) Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J 12:22–29. tpj201075 [pii]. https://doi.org/10.1038/tpj.2010.75
doi: 10.1038/tpj.2010.75
pubmed: 20921968
Tzvetkov MV, dos Santos Pereira JN, Meineke I, Saadatmand AR, Stingl JC, Brockmöller J (2013) Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem Pharmacol 86:666–678. S0006-2952(13)00390-0 [pii]. https://doi.org/10.1016/j.bcp.2013.06.019
doi: 10.1016/j.bcp.2013.06.019
pubmed: 23835420
Tzvetkov MV, Matthaei J, Pojar S, Faltraco F, Vogler S, Prukop T, Seitz T, Brockmöller J (2018) Increased systemic exposure and stronger cardiovascular and metabolic adverse reactions to fenoterol in individuals with heritable OCT1 deficiency. Clin Pharmacol Ther 103:868–878. https://doi.org/10.1002/cpt.812
doi: 10.1002/cpt.812
pubmed: 28791698
Usui T, Nakazawa A, Okura T, Deguchi Y, Akanuma SI, Kubo Y, Hosoya KI (2016) Histamine elimination from the cerebrospinal fluid across the blood-cerebrospinal fluid barrier: involvement of plasma membrane monoamine transporter (PMAT/SLC29A4). J Neurochem 139:408–418. https://doi.org/10.1111/jnc.13758
doi: 10.1111/jnc.13758
pubmed: 27501284
Vialou V, Amphoux A, Zwart R, Giros B, Gautron S (2004) Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci 24:2846–2851
pubmed: 15028779
pmcid: 6729503
doi: 10.1523/JNEUROSCI.5147-03.2004
Vialou V, Balasse L, Dumas S, Giros B, Gautron S (2007) Neurochemical characterization of pathways expressing plasma membrane monoamine transporter in the rat brain. Neuroscience 144:616–622. https://doi.org/10.1016/j.neuroscience.2006.09.058
doi: 10.1016/j.neuroscience.2006.09.058
pubmed: 17110048
Vialou V, Balasse L, Callebert J, Launay J-M, Giros B, Gautron S (2008) Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice. J Neurochem 106:1471–1482
pubmed: 18513366
Wagner DJ, Sager JE, Duan H, Isoherranen N, Wang J (2017) Interaction and transport of methamphetamine and its primary metabolites by organic cation and multidrug and toxin extrusion transporters. Drug Metab Dispos. dmd.116.074708 [pii]. https://doi.org/10.1124/dmd.116.074708
Wang J (2016) The plasma membrane monoamine transporter (PMAT): structure, function, and role in organic cation disposition. Clin Pharmacol Ther 100:489–499. https://doi.org/10.1002/cpt.442
doi: 10.1002/cpt.442
pubmed: 27506881
Williams GV, Millar J (1990) Concentration-dependent actions of stimulated dopamine release on neuronal activity in rat striatum. Neuroscience 39:1–16. https://doi.org/10.1016/0306-4522(90)90217-r
doi: 10.1016/0306-4522(90)90217-r
pubmed: 2089272
Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y, Giacomini KM (2013) Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem 56:781–795. https://doi.org/10.1021/jm301302s
doi: 10.1021/jm301302s
pubmed: 23241029
pmcid: 4068829
Wu X, Gu HH (1999) Molecular cloning of the mouse dopamine transporter and pharmacological comparison with the human homologue. Gene 233:163–170. https://doi.org/10.1016/s0378-1119(99)00143-2
doi: 10.1016/s0378-1119(99)00143-2
pubmed: 10375632
Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V (1998a) Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem 273:32776–32786. https://doi.org/10.1074/jbc.273.49.32776
doi: 10.1074/jbc.273.49.32776
pubmed: 9830022
Wu X, Prasad PD, Leibach FH, Ganapathy V (1998b) cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun 246:589–595. https://doi.org/10.1006/bbrc.1998.8669
doi: 10.1006/bbrc.1998.8669
pubmed: 9618255
Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V (2000) Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol 279:F449–F458
pubmed: 10966924
doi: 10.1152/ajprenal.2000.279.3.F449
Wu KC, Lu YH, Peng YH, Hsu LC, Lin CJ (2015a) Effects of lipopolysaccharide on the expression of plasma membrane monoamine transporter (PMAT) at the blood-brain barrier and its implications to the transport of neurotoxins. J Neurochem 135:1178–1188. https://doi.org/10.1111/jnc.13363
doi: 10.1111/jnc.13363
pubmed: 26376205
Wu KC, Lu YH, Peng YH, Tsai TF, Kao YH, Yang HT, Lin CJ (2015b) Decreased expression of organic cation transporters, Oct1 and Oct2, in brain microvessels and its implication to MPTP-induced dopaminergic toxicity in aged mice. J Cereb Blood Flow Metab 35:37–47. jcbfm2014162 [pii]. https://doi.org/10.1038/jcbfm.2014.162
doi: 10.1038/jcbfm.2014.162
pubmed: 25248837
Wyler SC, Donovan LJ, Yeager M, Deneris E (2015) Pet-1 controls tetrahydrobiopterin pathway and Slc22a3 transporter genes in serotonin neurons. ACS Chem Nerosci 6:1198–1205. https://doi.org/10.1021/cn500331z
doi: 10.1021/cn500331z
Xu F, Gainetdinov RR, Wetsel WC, Jones SR, Bohn LM, Miller GW, Wang YM, Caron MG (2000) Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nat Neurosci 3:465–471. https://doi.org/10.1038/74839
doi: 10.1038/74839
pubmed: 10769386
Yoshikawa T, Yanai K (2017) Histamine clearance through polyspecific transporters in the brain. Handb Exp Pharmacol 241:173–187. https://doi.org/10.1007/164_2016_13
doi: 10.1007/164_2016_13
pubmed: 27679412
Yoshikawa T, Naganuma F, Iida T, Nakamura T, Harada R, Mohsen AS, Kasajima A, Sasano H, Yanai K (2013) Molecular mechanism of histamine clearance by primary human astrocytes. Glia 61:905–916. https://doi.org/10.1002/glia.22484
doi: 10.1002/glia.22484
pubmed: 23505051
Zhang L, Schaner ME, Giacomini KM (1998) Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther 286:354–361
pubmed: 9655880
Zhou FC, Tao-Cheng JH, Segu L, Patel T, Wang Y (1998) Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence. Brain Res 805:241–254. https://doi.org/10.1016/s0006-8993(98)00691-x
doi: 10.1016/s0006-8993(98)00691-x
pubmed: 9733975
Zhou FC, Lesch KP, Murphy DL (2002) Serotonin uptake into dopamine neurons via dopamine transporters: a compensatory alternative. Brain Res 942:109–119. https://doi.org/10.1016/s0006-8993(02)02709-9
doi: 10.1016/s0006-8993(02)02709-9
pubmed: 12031859
Zhou FM, Liang Y, Salas R, Zhang L, De Biasi M, Dani JA (2005) Corelease of dopamine and serotonin from striatal dopamine terminals. Neuron 46:65–74. https://doi.org/10.1016/j.neuron.2005.02.010
doi: 10.1016/j.neuron.2005.02.010
pubmed: 15820694
Zhou M, Engel K, Wang J (2007) Evidence for significant contribution of a newly identified monoamine transporter (PMAT) to serotonin uptake in the human brain. Biochem Pharmacol 73:147–154. https://doi.org/10.1016/j.bcp.2006.09.008
doi: 10.1016/j.bcp.2006.09.008
pubmed: 17046718
Zhu H-J, Appel DI, Gründemann D, Markowitz JS (2010) Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem 114(1):142–149
pubmed: 20402963
pmcid: 3775896
Zhu HJ, Appel DI, Grundemann D, Richelson E, Markowitz JS (2012) Evaluation of organic cation transporter 3 (SLC22A3) inhibition as a potential mechanism of antidepressant action. Pharmacol Res 65:491–496. https://doi.org/10.1016/j.phrs.2012.01.008
doi: 10.1016/j.phrs.2012.01.008
pubmed: 22342816
Zhu P, Ye Z, Guo D, Xiong Z, Huang S, Guo J, Zhang W, Polli JE, Zhou H, Li QS, Hu Y (2018) Irinotecan alters the disposition of morphine via inhibition of organic cation transporter 1 (OCT1) and 2 (OCT2). Pharm Res 35:243. https://doi.org/10.1007/s11095-018-2526-y
Zoli M, Torri C, Ferrari R, Jansson A, Zini I, Fuxe K, Agnati LF (1998) The emergence of the volume transmission concept. Brain Res Brain Res Rev 26:136–147. https://doi.org/10.1016/s0165-0173(97)00048-9
doi: 10.1016/s0165-0173(97)00048-9
pubmed: 9651506
Zolk O, Solbach TF, Konig J, Fromm MF (2009a) Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch Pharmacol 379:337–348. https://doi.org/10.1007/s00210-008-0369-5
doi: 10.1007/s00210-008-0369-5
pubmed: 19002438
Zolk O, Solbach TF, König J, Fromm MF (2009b) Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab Dispos 37:1312–1318
pubmed: 19251820
doi: 10.1124/dmd.108.023762